Clinical trials: Alopecia Areata
Central Centrifugal Cicatricial Alopecia
A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia
The purpose of this study is to determine if the Revian Red All LED cap shows potential to be an effective treatment for Central centrifugal cicatricial alopecia (CCCA) by recruiting hair follicles back to anagen growth or by…
- Trial name
- NCT05759338
- Testing
- Revian Red All LED cap
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Psoriasis (PsO), Vitiligo Vulgaris
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
Primary objective: The primary objective is to evaluate in the general population the difference between emotional reactions associated with facial involvement by four major dermatologic diseases: psoriasis, atopic dermatitis…
- Conditions
- Psoriasis (PsO), Vitiligo Vulgaris, Atopic Dermatitis, Areata Alopecia
- Trial name
- STIGMADERM (NCT06801821)
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Androgenic Alopecia
Umbilical Cord-derived Mesenchymal Stem Cell Exosomes on Hair Growth in Patients With Androgenetic Alopecia
A total of 50 patients with androgenetic alopecia were selected for the study. Patients who met the inclusion/exclusion criteria were randomly assigned to groups A and B in a 1:1 ratio to receive treatment, with the enrollment…
- Trial name
- NCT06697080
- Testing
- Human umbilical cord mesenchymal stem cells
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Androgenetic Alopecia (AGA)
Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia
The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults.
- Trial name
- NCT07012486
- Testing
- Oral DHA + Topical minoxidil 5%, Topical Minoxidil 5%
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Alopecia Areata
CorEvitas International Adolescent Alopecia Areata (AA) Drug Safety and Effectiveness Registry
Prospective observational registry focusing on an adolescent cohort diagnosed with severe alopecia areata,receiving routine care from dermatology providers.
- Trial name
- NCT06562270
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- CorEvitas
Alopecia, Androgenetic
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
The purpose of the study is to see if Clascoterone can help people with male pattern hair loss to recovery and see if the treatment is effective and safe and how well the drug is tolerated by subjects.
- Trial name
- SCALP2 (NCT05914805)
- Testing
- Clascoterone 5% solution, Vehicle solution
- Where
- 27 sites in United States, Germany and 1 more
- Volunteers
- 762 people
- Sponsor
- Cassiopea SpA
Breast Cancer, Metastatic Breast Cancer
Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer
HALACAP-1406 is a prospective single-centre non-interventional study assessing the refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®) in the conditions of use specified in its marketing…
- Trial name
- NCT02863146
- Where
- France
- Volunteers
- 23 people
- Sponsor
- Centre Oscar Lambret
Hair Thinning
Pilot Study to Evaluate the Efficacy and Safety of Xvie Delivered Into the Scalp by Microneedling in Women With Self-perceived Thinning Hair
The goal of this study is to determine how safe and effective it is to improve hair growth using XVIE solution applied on the scalp of women with self-perceived thinning hair. The main aims of this trial are: 1.
- Trial name
- NCT07221773
- Testing
- XVIE
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Restore Biologics Holdings, Inc. dba Xtressé
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients
This phase II trial compares the safety and effectiveness of topical minoxidil alone to topical minoxidil in combination with low-level red-light therapy for improving chemotherapy-induced hair loss or thinning (alopecia).
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT07594678
- Testing
- Electronic Health Record Review, Minoxidil, Revian RED LED-light cap
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Androgenic Alopecia
A Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth
The goal of this clinical study is to evaluate the efficacy and safety of the Ultra device for the treatment of hair regrowth by assessing the improvement of hair density and hair shaft diameter.
- Trial name
- NCT07588243
- Testing
- Low Level Laser Therapy
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- CynosureLutronic
Androgenic Alopecia
A Clinical Study to Assess Safety, Efficacy and In-use Tolerability of Different Dosages of Hair Growth Products in Patients With Mild to Moderate Androgenic Alopecia (Grade I to III).
This is a prospective, interventional, exploratory, four-arm - dose response study, comparative, double-blind, randomized, placebo-control, proof of concept, safety, efficacy and in-use tolerability study of three different…
- Trial name
- NCT06551818
- Testing
- SesZen-Bio Low Dose 1 (350 mg extract), SesZen-Bio Low Dose 1 (150 mg liposomal), SesZen-Bio High Dose 1 (500 mg extract)
- Where
- India
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- NovoBliss Research Pvt Ltd
Hair Loss
Ocular Finding in Alopecia Areata
Alopecia areata (AA) is a common, idiopathic and sometimes recurrent non-scarring type of hair loss. Several etiological factors, including psychological, trauma-related, genetic and autoimmune factors have been considered as…
- Trial name
- NCT03155958
- Volunteers
- 1 people
- Sponsor
- Assiut University
Alopecia Areata
Fecal Transplant for Alopecia Areata
the investigators intend to analyze the microbiome in the diseased areas, healthy skin and fecal samples. In addition, the investigators plan to evaluate how the fecal transplant can influence the severity of the disease and hair…
- Trial name
- NCT04833179
- Testing
- fecal transplant
- Volunteers
- 110 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Alopecia, Rheumatoid Arthritis
Hair Fall in Patients on Low Dose Methotrexate
Low dose methotrexate used in rheumatoid arthritis is considered very safe and has a side effect profile very different from that seen with high dose methotrexate used in oncology.
- Conditions
- Alopecia, Rheumatoid Arthritis, Methotrexate Adverse Reaction
- Trial name
- NCT02591823
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Columbia Asia
Alopecia, Alopecia, Androgenetic
Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)
This is a safety, tolerability, and pharmacokinetics study of bimatoprost in male patients with androgenetic alopecia (AGA).
- Conditions
- Alopecia, Alopecia, Androgenetic, Baldness
- Trial name
- NCT02676310
- Testing
- Bimatoprost
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Allergan
Alopecia
A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia
This is a multicentre, open-label study to assess the safety, tolerability, and efficacy of 0.5 mg Dutasteride administered once daily for 52 weeks in men with Androgenetic Alopecia types III vertex, IV and V per the…
- Trial name
- NCT01831791
- Testing
- Dutasteride 0.5 mg
- Where
- 5 sites in Japan
- Volunteers
- 120 people
- Sponsor
- GlaxoSmithKline
Hair Care, Hair Loss
Olistic_2025 for Hair Loss, Hair Growth, and Skin Improvement
The goal of this randomized, double-blind, placebo-controlled clinical trial is to find out whether daily oral intake of the nutraceutical Olistic Next Women can reduce hair loss, improve hair growth and quality, and improve…
- Conditions
- Hair Care, Hair Loss, Female Pattern Hair Loss
- Trial name
- NCT07300813
- Testing
- Olistic Next Women
- Where
- Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bionos Biotech S.L.
Androgenetic Alopecia
Phase III Study of KX-826 With Adult Male Patients With AGA
This is a phase III, multi-center, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of KX-826 for topical use in Chinese adult male patients with androgenetic alopecia (AGA).
- Trial name
- NCT06126965
- Testing
- KX-826-（5%） BID
- Where
- 26 sites in China
- Volunteers
- 740 people
- Sponsor
- Suzhou Kintor Pharmaceutical Inc,
Frontal Fibrosing Alopecia, Cicatricial Alopecia
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often used to treat FFA, but it is not…
- Trial name
- NCT07190534
- Testing
- Hydroxychloroquine (HCQ), Methotrexate (MTX)
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Erasmus Medical Center
Androgenic Alopecia
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
The study team will assess the efficacy of platelet-rich plasma therapy, a special blood product which is from the participant's own body, in the treatment of androgenic alopecia (also known as male pattern hair loss) in females.
- Trial name
- NCT03474718
- Testing
- Platelet-rich Plasma Left Side, Platelet-rich Plasma Right Side
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Wake Forest University Health Sciences